Living donor liver transplantation or hepatic resection combined with intraoperative radiofrequency ablation for Child–Pugh A hepatocellular carcinoma patient with Multifocal Tumours Meeting the University of California San Francisco (UCSF) criteria
Background How much difference there is between hepatic resection (HR) combined with intraoperative radiofrequency ablation (RFA) and living donor liver transplantation (LDLT) in treatment of multifocal hepatocellular carcinomas (HCCs) remains unclear. This study compared outcomes for patients with...
Gespeichert in:
Veröffentlicht in: | Journal of cancer research and clinical oncology 2021-02, Vol.147 (2), p.607-618 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 618 |
---|---|
container_issue | 2 |
container_start_page | 607 |
container_title | Journal of cancer research and clinical oncology |
container_volume | 147 |
creator | Xu, Xi Pu, Xingyu Jiang, Li Huang, Yang Yan, Lunan Yang, Jiayin Wen, Tianfu Li, Bo Wu, Hong Wang, Wentao |
description | Background
How much difference there is between hepatic resection (HR) combined with intraoperative radiofrequency ablation (RFA) and living donor liver transplantation (LDLT) in treatment of multifocal hepatocellular carcinomas (HCCs) remains unclear. This study compared outcomes for patients with multifocal HCCs meeting the University of California San Francisco (UCSF) criteria treated by LDLT or HR + RFA.
Methods
A total of 126 consecutive Child–Pugh A patients with multifocal HCCs meeting the UCSF criteria, who underwent LDLT (
n
= 51) or HR + RFA (
n
= 75), were included. Propensity score (PS) matching was performed to adjust for baseline differences. Overall survival (OS) and recurrence-free survival (RFS) were calculated, and subgroup, multivariate and nomogram analyses were performed.
Results
LDLT provided significantly better OS and RFS than did HR + RFA before and after PS matching and reduced the dropout rate on waiting list, but HR + RFA was more convenient, less invasive and less cost. Patients with all lesions located in the same lobe had better OS and RFS than those located in the different lobes after HR + RFA. Multivariate and nomogram analyses revealed that HR + RFA, alpha-fetoprotein ≥ 400 ng/mL, the major tumour size > 3 cm and microvascular invasion were independent predictors of poor prognosis.
Conclusion
For Child–Pugh A patients with multiple HCCs meeting the UCSF criteria, LDLT may offer significantly better long-term results than did HR + RFA, and HR + RFA may still be considered as an acceptable curative therapy for those without considering transplantation or as a bridge treatment for a patient, with a plan for transplantation in the future. |
doi_str_mv | 10.1007/s00432-020-03364-x |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2437850134</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2479207541</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-68cf16876a861120cf311e2dcaf6ebdc20880c2e305193afb0caf3d3f0ddc9103</originalsourceid><addsrcrecordid>eNp9ks1uEzEQx1cIREPhBTigkbiUw4I_sh85VhGhSKlAanNeeb3jxJXXXmxv2tx4B96Q1-BSp1tA4sDJ9sxv_jNj_bPsNSXvKSHVh0DInLOcMJITzst5fvckm9FjiHJePM1mhFY0LxgtT7IXIdyQ9C4q9jw74awuWMmLWfZrrffabqFz1nkweo8eohc2DEbYKKJ2FlJih0O6S_AYUD4EpetbbbGDWx13oG0qcgP6RO0RvOi0Ux6_jWjlAURrJiWVpJY7bbqf3398Hbc7OJ-UnURjRiM8SOGltq4XcGyINk76l6OJWjkpDFyPvRt9gEvEeJw87hA29jh40PEATsFSmMR6qwVcCQurtI7UQTo42yyvVu9Aeh3Ra_Eye6aECfjq8TzNNquP18uLfP3l0-fl-TqXvCpiXtZS0bKuSlGXlDIiFacUWSeFKrHtJCN1TSRDTgq64EK1JGV4xxXpOrmghJ9mZ5Pu4F36kRCbPo2TNhYW3RgaNudVXRDK5wl9-w96k5a1abpEVQtGqmJOE8UmSnoXgkfVDF73wh8aSpqjNZrJGk2yRvNgjeYuFb15lB7bHrs_Jb-9kAA-ASGl7Bb9397_kb0HUQTNCQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2479207541</pqid></control><display><type>article</type><title>Living donor liver transplantation or hepatic resection combined with intraoperative radiofrequency ablation for Child–Pugh A hepatocellular carcinoma patient with Multifocal Tumours Meeting the University of California San Francisco (UCSF) criteria</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Xu, Xi ; Pu, Xingyu ; Jiang, Li ; Huang, Yang ; Yan, Lunan ; Yang, Jiayin ; Wen, Tianfu ; Li, Bo ; Wu, Hong ; Wang, Wentao</creator><creatorcontrib>Xu, Xi ; Pu, Xingyu ; Jiang, Li ; Huang, Yang ; Yan, Lunan ; Yang, Jiayin ; Wen, Tianfu ; Li, Bo ; Wu, Hong ; Wang, Wentao</creatorcontrib><description>Background
How much difference there is between hepatic resection (HR) combined with intraoperative radiofrequency ablation (RFA) and living donor liver transplantation (LDLT) in treatment of multifocal hepatocellular carcinomas (HCCs) remains unclear. This study compared outcomes for patients with multifocal HCCs meeting the University of California San Francisco (UCSF) criteria treated by LDLT or HR + RFA.
Methods
A total of 126 consecutive Child–Pugh A patients with multifocal HCCs meeting the UCSF criteria, who underwent LDLT (
n
= 51) or HR + RFA (
n
= 75), were included. Propensity score (PS) matching was performed to adjust for baseline differences. Overall survival (OS) and recurrence-free survival (RFS) were calculated, and subgroup, multivariate and nomogram analyses were performed.
Results
LDLT provided significantly better OS and RFS than did HR + RFA before and after PS matching and reduced the dropout rate on waiting list, but HR + RFA was more convenient, less invasive and less cost. Patients with all lesions located in the same lobe had better OS and RFS than those located in the different lobes after HR + RFA. Multivariate and nomogram analyses revealed that HR + RFA, alpha-fetoprotein ≥ 400 ng/mL, the major tumour size > 3 cm and microvascular invasion were independent predictors of poor prognosis.
Conclusion
For Child–Pugh A patients with multiple HCCs meeting the UCSF criteria, LDLT may offer significantly better long-term results than did HR + RFA, and HR + RFA may still be considered as an acceptable curative therapy for those without considering transplantation or as a bridge treatment for a patient, with a plan for transplantation in the future.</description><identifier>ISSN: 0171-5216</identifier><identifier>EISSN: 1432-1335</identifier><identifier>DOI: 10.1007/s00432-020-03364-x</identifier><identifier>PMID: 32852635</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Ablation ; Adult ; Aged ; Cancer Research ; Carcinoma, Hepatocellular - mortality ; Carcinoma, Hepatocellular - pathology ; Carcinoma, Hepatocellular - surgery ; Female ; Hematology ; Hepatectomy ; Hepatocellular carcinoma ; Humans ; Internal Medicine ; Invasiveness ; Liver cancer ; Liver Neoplasms - mortality ; Liver Neoplasms - pathology ; Liver Neoplasms - surgery ; Liver Transplantation ; Liver transplants ; Living Donors ; Male ; Medical prognosis ; Medicine ; Medicine & Public Health ; Microvasculature ; Middle Aged ; Neoplasm Recurrence, Local ; Nomograms ; Oncology ; Original Article – Clinical Oncology ; Patients ; Radiofrequency Ablation ; Survival ; Tumors ; α-Fetoprotein</subject><ispartof>Journal of cancer research and clinical oncology, 2021-02, Vol.147 (2), p.607-618</ispartof><rights>Springer-Verlag GmbH Germany, part of Springer Nature 2020</rights><rights>Springer-Verlag GmbH Germany, part of Springer Nature 2020.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-68cf16876a861120cf311e2dcaf6ebdc20880c2e305193afb0caf3d3f0ddc9103</citedby><cites>FETCH-LOGICAL-c375t-68cf16876a861120cf311e2dcaf6ebdc20880c2e305193afb0caf3d3f0ddc9103</cites><orcidid>0000-0003-0224-4749</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00432-020-03364-x$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00432-020-03364-x$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32852635$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Xu, Xi</creatorcontrib><creatorcontrib>Pu, Xingyu</creatorcontrib><creatorcontrib>Jiang, Li</creatorcontrib><creatorcontrib>Huang, Yang</creatorcontrib><creatorcontrib>Yan, Lunan</creatorcontrib><creatorcontrib>Yang, Jiayin</creatorcontrib><creatorcontrib>Wen, Tianfu</creatorcontrib><creatorcontrib>Li, Bo</creatorcontrib><creatorcontrib>Wu, Hong</creatorcontrib><creatorcontrib>Wang, Wentao</creatorcontrib><title>Living donor liver transplantation or hepatic resection combined with intraoperative radiofrequency ablation for Child–Pugh A hepatocellular carcinoma patient with Multifocal Tumours Meeting the University of California San Francisco (UCSF) criteria</title><title>Journal of cancer research and clinical oncology</title><addtitle>J Cancer Res Clin Oncol</addtitle><addtitle>J Cancer Res Clin Oncol</addtitle><description>Background
How much difference there is between hepatic resection (HR) combined with intraoperative radiofrequency ablation (RFA) and living donor liver transplantation (LDLT) in treatment of multifocal hepatocellular carcinomas (HCCs) remains unclear. This study compared outcomes for patients with multifocal HCCs meeting the University of California San Francisco (UCSF) criteria treated by LDLT or HR + RFA.
Methods
A total of 126 consecutive Child–Pugh A patients with multifocal HCCs meeting the UCSF criteria, who underwent LDLT (
n
= 51) or HR + RFA (
n
= 75), were included. Propensity score (PS) matching was performed to adjust for baseline differences. Overall survival (OS) and recurrence-free survival (RFS) were calculated, and subgroup, multivariate and nomogram analyses were performed.
Results
LDLT provided significantly better OS and RFS than did HR + RFA before and after PS matching and reduced the dropout rate on waiting list, but HR + RFA was more convenient, less invasive and less cost. Patients with all lesions located in the same lobe had better OS and RFS than those located in the different lobes after HR + RFA. Multivariate and nomogram analyses revealed that HR + RFA, alpha-fetoprotein ≥ 400 ng/mL, the major tumour size > 3 cm and microvascular invasion were independent predictors of poor prognosis.
Conclusion
For Child–Pugh A patients with multiple HCCs meeting the UCSF criteria, LDLT may offer significantly better long-term results than did HR + RFA, and HR + RFA may still be considered as an acceptable curative therapy for those without considering transplantation or as a bridge treatment for a patient, with a plan for transplantation in the future.</description><subject>Ablation</subject><subject>Adult</subject><subject>Aged</subject><subject>Cancer Research</subject><subject>Carcinoma, Hepatocellular - mortality</subject><subject>Carcinoma, Hepatocellular - pathology</subject><subject>Carcinoma, Hepatocellular - surgery</subject><subject>Female</subject><subject>Hematology</subject><subject>Hepatectomy</subject><subject>Hepatocellular carcinoma</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Invasiveness</subject><subject>Liver cancer</subject><subject>Liver Neoplasms - mortality</subject><subject>Liver Neoplasms - pathology</subject><subject>Liver Neoplasms - surgery</subject><subject>Liver Transplantation</subject><subject>Liver transplants</subject><subject>Living Donors</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Microvasculature</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local</subject><subject>Nomograms</subject><subject>Oncology</subject><subject>Original Article – Clinical Oncology</subject><subject>Patients</subject><subject>Radiofrequency Ablation</subject><subject>Survival</subject><subject>Tumors</subject><subject>α-Fetoprotein</subject><issn>0171-5216</issn><issn>1432-1335</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9ks1uEzEQx1cIREPhBTigkbiUw4I_sh85VhGhSKlAanNeeb3jxJXXXmxv2tx4B96Q1-BSp1tA4sDJ9sxv_jNj_bPsNSXvKSHVh0DInLOcMJITzst5fvckm9FjiHJePM1mhFY0LxgtT7IXIdyQ9C4q9jw74awuWMmLWfZrrffabqFz1nkweo8eohc2DEbYKKJ2FlJih0O6S_AYUD4EpetbbbGDWx13oG0qcgP6RO0RvOi0Ux6_jWjlAURrJiWVpJY7bbqf3398Hbc7OJ-UnURjRiM8SOGltq4XcGyINk76l6OJWjkpDFyPvRt9gEvEeJw87hA29jh40PEATsFSmMR6qwVcCQurtI7UQTo42yyvVu9Aeh3Ra_Eye6aECfjq8TzNNquP18uLfP3l0-fl-TqXvCpiXtZS0bKuSlGXlDIiFacUWSeFKrHtJCN1TSRDTgq64EK1JGV4xxXpOrmghJ9mZ5Pu4F36kRCbPo2TNhYW3RgaNudVXRDK5wl9-w96k5a1abpEVQtGqmJOE8UmSnoXgkfVDF73wh8aSpqjNZrJGk2yRvNgjeYuFb15lB7bHrs_Jb-9kAA-ASGl7Bb9397_kb0HUQTNCQ</recordid><startdate>20210201</startdate><enddate>20210201</enddate><creator>Xu, Xi</creator><creator>Pu, Xingyu</creator><creator>Jiang, Li</creator><creator>Huang, Yang</creator><creator>Yan, Lunan</creator><creator>Yang, Jiayin</creator><creator>Wen, Tianfu</creator><creator>Li, Bo</creator><creator>Wu, Hong</creator><creator>Wang, Wentao</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-0224-4749</orcidid></search><sort><creationdate>20210201</creationdate><title>Living donor liver transplantation or hepatic resection combined with intraoperative radiofrequency ablation for Child–Pugh A hepatocellular carcinoma patient with Multifocal Tumours Meeting the University of California San Francisco (UCSF) criteria</title><author>Xu, Xi ; Pu, Xingyu ; Jiang, Li ; Huang, Yang ; Yan, Lunan ; Yang, Jiayin ; Wen, Tianfu ; Li, Bo ; Wu, Hong ; Wang, Wentao</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-68cf16876a861120cf311e2dcaf6ebdc20880c2e305193afb0caf3d3f0ddc9103</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Ablation</topic><topic>Adult</topic><topic>Aged</topic><topic>Cancer Research</topic><topic>Carcinoma, Hepatocellular - mortality</topic><topic>Carcinoma, Hepatocellular - pathology</topic><topic>Carcinoma, Hepatocellular - surgery</topic><topic>Female</topic><topic>Hematology</topic><topic>Hepatectomy</topic><topic>Hepatocellular carcinoma</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Invasiveness</topic><topic>Liver cancer</topic><topic>Liver Neoplasms - mortality</topic><topic>Liver Neoplasms - pathology</topic><topic>Liver Neoplasms - surgery</topic><topic>Liver Transplantation</topic><topic>Liver transplants</topic><topic>Living Donors</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Microvasculature</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local</topic><topic>Nomograms</topic><topic>Oncology</topic><topic>Original Article – Clinical Oncology</topic><topic>Patients</topic><topic>Radiofrequency Ablation</topic><topic>Survival</topic><topic>Tumors</topic><topic>α-Fetoprotein</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Xu, Xi</creatorcontrib><creatorcontrib>Pu, Xingyu</creatorcontrib><creatorcontrib>Jiang, Li</creatorcontrib><creatorcontrib>Huang, Yang</creatorcontrib><creatorcontrib>Yan, Lunan</creatorcontrib><creatorcontrib>Yang, Jiayin</creatorcontrib><creatorcontrib>Wen, Tianfu</creatorcontrib><creatorcontrib>Li, Bo</creatorcontrib><creatorcontrib>Wu, Hong</creatorcontrib><creatorcontrib>Wang, Wentao</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of cancer research and clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Xu, Xi</au><au>Pu, Xingyu</au><au>Jiang, Li</au><au>Huang, Yang</au><au>Yan, Lunan</au><au>Yang, Jiayin</au><au>Wen, Tianfu</au><au>Li, Bo</au><au>Wu, Hong</au><au>Wang, Wentao</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Living donor liver transplantation or hepatic resection combined with intraoperative radiofrequency ablation for Child–Pugh A hepatocellular carcinoma patient with Multifocal Tumours Meeting the University of California San Francisco (UCSF) criteria</atitle><jtitle>Journal of cancer research and clinical oncology</jtitle><stitle>J Cancer Res Clin Oncol</stitle><addtitle>J Cancer Res Clin Oncol</addtitle><date>2021-02-01</date><risdate>2021</risdate><volume>147</volume><issue>2</issue><spage>607</spage><epage>618</epage><pages>607-618</pages><issn>0171-5216</issn><eissn>1432-1335</eissn><abstract>Background
How much difference there is between hepatic resection (HR) combined with intraoperative radiofrequency ablation (RFA) and living donor liver transplantation (LDLT) in treatment of multifocal hepatocellular carcinomas (HCCs) remains unclear. This study compared outcomes for patients with multifocal HCCs meeting the University of California San Francisco (UCSF) criteria treated by LDLT or HR + RFA.
Methods
A total of 126 consecutive Child–Pugh A patients with multifocal HCCs meeting the UCSF criteria, who underwent LDLT (
n
= 51) or HR + RFA (
n
= 75), were included. Propensity score (PS) matching was performed to adjust for baseline differences. Overall survival (OS) and recurrence-free survival (RFS) were calculated, and subgroup, multivariate and nomogram analyses were performed.
Results
LDLT provided significantly better OS and RFS than did HR + RFA before and after PS matching and reduced the dropout rate on waiting list, but HR + RFA was more convenient, less invasive and less cost. Patients with all lesions located in the same lobe had better OS and RFS than those located in the different lobes after HR + RFA. Multivariate and nomogram analyses revealed that HR + RFA, alpha-fetoprotein ≥ 400 ng/mL, the major tumour size > 3 cm and microvascular invasion were independent predictors of poor prognosis.
Conclusion
For Child–Pugh A patients with multiple HCCs meeting the UCSF criteria, LDLT may offer significantly better long-term results than did HR + RFA, and HR + RFA may still be considered as an acceptable curative therapy for those without considering transplantation or as a bridge treatment for a patient, with a plan for transplantation in the future.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>32852635</pmid><doi>10.1007/s00432-020-03364-x</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0003-0224-4749</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0171-5216 |
ispartof | Journal of cancer research and clinical oncology, 2021-02, Vol.147 (2), p.607-618 |
issn | 0171-5216 1432-1335 |
language | eng |
recordid | cdi_proquest_miscellaneous_2437850134 |
source | MEDLINE; SpringerLink Journals - AutoHoldings |
subjects | Ablation Adult Aged Cancer Research Carcinoma, Hepatocellular - mortality Carcinoma, Hepatocellular - pathology Carcinoma, Hepatocellular - surgery Female Hematology Hepatectomy Hepatocellular carcinoma Humans Internal Medicine Invasiveness Liver cancer Liver Neoplasms - mortality Liver Neoplasms - pathology Liver Neoplasms - surgery Liver Transplantation Liver transplants Living Donors Male Medical prognosis Medicine Medicine & Public Health Microvasculature Middle Aged Neoplasm Recurrence, Local Nomograms Oncology Original Article – Clinical Oncology Patients Radiofrequency Ablation Survival Tumors α-Fetoprotein |
title | Living donor liver transplantation or hepatic resection combined with intraoperative radiofrequency ablation for Child–Pugh A hepatocellular carcinoma patient with Multifocal Tumours Meeting the University of California San Francisco (UCSF) criteria |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T16%3A01%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Living%20donor%20liver%20transplantation%20or%20hepatic%20resection%20combined%20with%20intraoperative%20radiofrequency%20ablation%20for%20Child%E2%80%93Pugh%20A%20hepatocellular%20carcinoma%20patient%20with%20Multifocal%20Tumours%20Meeting%20the%20University%20of%20California%20San%20Francisco%20(UCSF)%20criteria&rft.jtitle=Journal%20of%20cancer%20research%20and%20clinical%20oncology&rft.au=Xu,%20Xi&rft.date=2021-02-01&rft.volume=147&rft.issue=2&rft.spage=607&rft.epage=618&rft.pages=607-618&rft.issn=0171-5216&rft.eissn=1432-1335&rft_id=info:doi/10.1007/s00432-020-03364-x&rft_dat=%3Cproquest_cross%3E2479207541%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2479207541&rft_id=info:pmid/32852635&rfr_iscdi=true |